MOR 106

Drug Profile

MOR 106

Alternative Names: MOR106

Latest Information Update: 30 Sep 2016

Price : $50

At a glance

  • Originator Galapagos NV; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Atopic dermatitis; Inflammation

Most Recent Events

  • 29 Sep 2016 Phase-I clinical trials in Atopic dermatitis in Europe (IV)
  • 07 Apr 2016 Phase-I clinical trials in Inflammation (In volunteers) in Belgium (IV)
  • 31 Dec 2015 Galapagos files for patent protection for MOR 106 (Galapagos Form 20F, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top